

Neue Erkenntnisse zur alten Frage: L-DOPA versus Dopaminagonisten

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

PD MED Collaborative Group*

1620 PPD Patienten über 7 Jahre untersucht:
L-DOPA versus DA, MAO-B-Hemmer



The Lancet 2014




Figure 5: Risk of developing dyskinesia in levodopa and levodopa-sparing groups




Figure 4: 39-item patient-rated Parkinson's disease questionnaire mobility score (A) and summary index (B) with time in levodopa and levodopa-sparing groups